AlloSource enrolled the first patient in a prospective, multi-center study evaluating ProChondrix CR® fresh cryopreserved osteochondral allograft, for the repair of focal articular cartilage defects in the knee.
AlloSource developed ProChondrix CR cartilage restoration therapy to provide live, functional cells, an intact extracellular matrix and other biological components for repair and regeneration of damaged cartilage. A two-year shelf life post-cryopreservation addresses the challenge of a short placement timeline, allowing more flexibility for hospitals and surgeons.
AlloSource enrolled the first patient in a prospective, multi-center study evaluating ProChondrix CR® fresh cryopreserved osteochondral allograft, for the repair of focal articular cartilage defects in the knee.
AlloSource developed ProChondrix CR cartilage restoration therapy to provide live, functional cells, an intact extracellular matrix...
AlloSource enrolled the first patient in a prospective, multi-center study evaluating ProChondrix CR® fresh cryopreserved osteochondral allograft, for the repair of focal articular cartilage defects in the knee.
AlloSource developed ProChondrix CR cartilage restoration therapy to provide live, functional cells, an intact extracellular matrix and other biological components for repair and regeneration of damaged cartilage. A two-year shelf life post-cryopreservation addresses the challenge of a short placement timeline, allowing more flexibility for hospitals and surgeons.
Copy to clipboard 
